ClinicalTrials.gg
CompletedNCT03309891Updated Apr 20, 2020

Dose Finding Study of GX-H9 in Paeditaric Patients With Growth Hormone Deficiency

A Phase 2 interventional study of GX-H9 and Genotropin in Growth Hormone Deficiency, sponsored by Genexine, Inc.. Completed at 1 site in Ukraine. Open to participants aged 3 Years to 11 Years. Per ClinicalTrials.gov, last updated 2020-04-20.

Sponsored by Genexine, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 7 months after the study started (first participant enrolled Jan 2016, registered Sep 2017).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
56
Allocation
Randomized
Ages
3 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 11 studies in Dwarfism, Pituitary with a site in Ukraine — none open to participants now, none under way, none of them phase 3. Dwarfism, Pituitary · Ukraine.

Enrollment
9th of 11
56 · median 162
Started
2016
with 1 other
Phase 2
5 of 11
none open now
Registered
7th of 11
by date
Lead sponsor
1 of 11
Genexine, Inc.

Among the 11 studies in Dwarfism, Pituitary with a site in Ukraine, this one is the 9th largest by enrollment, is one of 2 that started in 2016, is one of 5 in phase 2, and was the 7th registered.

Dwarfism, Pituitary

252 studies on the registry are indexed under Dwarfism, Pituitary; 30 are open to participants now.

Browse Dwarfism, Pituitary studies →

Open to participants now

None of the 11 studies in Dwarfism, Pituitary with a site in Ukraine is open now. The open studies under Dwarfism, Pituitary, anywhere →

Who these studies take

Of the 20 Dwarfism, Pituitary studies recruiting now, 5 (25%) set no upper age limit and 12 (60%) stop at 75 or younger; 11 take children under 18; 4 take healthy volunteers.

This study: 3 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 11 studies in Dwarfism, Pituitary with a site in Ukraine as a file.
02

Study summary

This is a randomized, open-label, active controlled, Phase 2 study designed to assess the safety, tolerability, efficacy, pharmacokinetics, and pharmacodynamics of weekly and semi-monthly doses of GX-H9 in the treatment of Paediatric Growth Hormone Deficiency (PGHD) as compared to the standard of care daily rhGH treatment.

Read the detailed description

GX-H9 is a new hGH product fused to hybrid Fc in studies as a once-a-week and every other week dosing regimen designed to overcome the inconvenience of daily rhGH injections and is under the studies designed to determine if the safety profile is comparable to currently approved daily rhGH products. Obviating the need for daily injections may increase compliance and therefore efficacy, which would be of great benefit to both paediatric and adult patients with GHD and other disorders with associated growth impairment and need for hGH substitution.

03

Conditions studied

  • Growth Hormone Deficiency

Browse trials for

04

Who can participate

Ages eligible
3 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Pre-pubertal children with either isolated GHD, or GH insufficiency as part of multiple pituitary hormone insufficiency, idiopathic or organic GH insufficiency (e.g., due to pituitary tumor, pituitary or brain surgery):

    • Boys: 3 years ≤ boy's age ≤ 11 years
    • Girls: 3 years ≤ girl's age ≤ 10 years
  2. GHD confirmed by 2 different GH provocation tests with peak GH concentration below 10 ng/mL as described in consensus guidelines. Well documented historical GH provocation tests can be used for study eligibility providing that the tests are performed as defined in Appendix 2 (e.g. the same sampling time points). Data of each historical GH stimulation test will be reviewed by Medical Monitor and Sponsor in order to assess acceptance for the study
  3. Without prior exposure to any rhGH therapy
  4. Bone age (BA) is not older than chronological age and should not be greater than 9 years for girls and 10 years for boys
  5. Impaired height and height velocity defined as:

    • Height (HT) of at least 2.0 standard deviations (SD) below the mean height for chronological age (CA) and gender according to the standards from Prader et. al 1989, (HT SDS ≤ -2.0)
    • Annualized height velocity (HV) of at least 1 SD below the mean HV for chronological age and gender according to the standards of Prader et al (1989). The interval between two height measurements should be at least 6 months (but not longer than 18 months) before inclusion
  6. All subjects must have at least one cranial imaging study [magnetic resonance imaging (MRI) or computed tomography (CT)] prior to randomization:

    • To exclude intracranial causes of GHD in subjects without history of pituitary tumor [obtained within 6 months prior to signing, or
    • Subjects with a previously treated pituitary tumor must have no tumor progression for at least the past year [obtained within 3 months prior to informed consent signing, compared with a previous MRI or CT performed at least 12 months earlier]
    • If not performed within these specified time frames prior to informed consent signing, may be performed as a part of the screening procedures
  7. (BMI) must be within ±2 SD of mean BMI for the chronological age and sex according to the 2000 CDC standards
  8. Baseline IGF-1 level of at least 1 SD below the mean IGF-1 level standardized for age and sex (IGF-1 SDS≤ -1.0) according to the central laboratory reference values. One IGF-1 retest is allowed during the Screening period if first results were not higher than

    -0.85 SDS and if GH stimulation tests results and auxology parameters met eligibility criteria

  9. Children with normal fundoscopy (ophthalmoscopy) at screening (without signs/symptoms of intracranial hypertension as assessed by fundoscopy) - it is highly recommended to take a photograph (if equipment is available at the study center)
  10. Children with multiple hormonal deficiencies must be on stable replacement therapies for other hypothalamo-pituitary-organ axes for at least 3 months and 6 months for thyroid replacement therapy prior to Screening. Temporary adjustment of replacement therapy, as appropriate, is acceptable
  11. Normal 46 XX karyotype for girls
  12. Written informed consent of the parent or legal guardian of the subject and assent of the subject (if the subject can read)
  13. Parent or legal guardian who is capable and willing to administer the study drug

Exclusion criteria

Exclusion Criteria:

  1. History of radiation therapy or chemotherapy
  2. Malnourished children defined as:

    • Serum albumin below the lower limit of normal (LLN) according to the reference ranges of central laboratory; and
    • Serum iron below the lower limit of normal (LLN) according to the reference ranges of central laboratory; and
    • \<-2 SD for age and sex
  3. Children with psychosocial dwarfism
  4. Children born small for gestational age (SGA-birth weight and/or birth length \< -2 SD for gestational age according to the standards from Niklasson et al., 1991)
  5. Presence of anti-hGH antibodies at screening
  6. Any abnormality likely to affect growth or the ability to evaluate growth, such as, but not limited to, chronic diseases like renal insufficiency, spinal cord irradiation, etc.
  7. Subjects with diabetes mellitus
  8. Subjects with impaired fasting sugar (based on WHO; fasting blood sugar > 110mg/dl or 6.1 mmol/l) after repeated blood analysis
  9. Chromosomal abnormalities and medical syndromes (Turner's syndrome, Laron syndrome, Noonan syndrome, Prader-Willi syndrome, Russell-Silver Syndrome, SHOX mutations/deletions and skeletal dysplasias), with the exception of septo-optic dysplasia
  10. Evidence of closed epiphyses
  11. Concomitant administration of other treatments that may have an effect on growth such as anabolic steroids and methylphenidate for attention deficit hyperactivity disorder (ADHD), with the exception of hormone replacement therapies [thyroxine, hydrocortisone, desmopressin (DDAVP)]
  12. Children requiring therapy, other than treated for hypothalamo-pituitary-adrenal insufficiency in replacement doses who are taking a dose of greater than 400 μg/d of inhaled budesonide or equivalents for longer than 1 month during a calendar year (e.g. asthma)
  13. Major medical conditions and/or presence of to rhGH treatment
  14. Has a history of positive serology results to , and/or
  15. Subject who has a known or suspected to rhGH
  16. Other causes of short stature such as coeliac disease, hypothyroidism and rickets
  17. The subject and/or the parent/legal guardian are likely to be non-compliant in respect to study conduct
  18. Subject who has received an product, or has participated in a clinical study within 60 days before screening
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
56 participants (actual)

Study arms

  • Experimental
    Cohort 1

    GX-H9 subcutaneous injections (weekly)

    Drug: GX-H9

  • Experimental
    Cohort 2

    GX-H9 subcutaneous injections (weekly)

    Drug: GX-H9

  • Experimental
    Cohort 3

    GX-H9 subcutaneous injections (twice-monthly)

    Drug: GX-H9

  • Active comparator
    Cohort 4

    Genotropin subcutaneous injections (daily)

    Drug: Genotropin

Interventions

  • DrugGX-H9

    subcutaneous injection (weekly or twice-monthly)

  • subcutaneous injection (daily)

06

What researchers measure

Primary outcomes

  1. Annual height velocity in cm/year

    The primary efficacy variable was the AHV in cm/year at 6 months.

    Time frame: 6 months

Secondary outcomes

  1. Annualized Height velocity expressed in SDS

    Time frame: 3, 6, 12 and 24 months

  2. Change in height SDS (compared to baseline value)

    Time frame: 3, 6, 12 and 24 months

  3. Annualized height velocity expressed in cm/year

    Time frame: 3, 12 and 24 months

  4. Change in height expressed in cm

    Time frame: 3, 6, 12 and 24 months

  5. Change in absolute IGF-I levels

    Time frame: 25 months

  6. Change in IGF-I SDS

    Time frame: 25 months

  7. Change in absolute IGFBP-3 levels

    Time frame: 25 months

  8. Change in IGFBP-3 SDS

    Time frame: 25 months

  9. Bone maturation after 12 and 24 months of treatment;

    Time frame: 12 and 24 months

  10. Predicted adult height change from start to 12 and 24 months

    Time frame: 12 and 24 months

  11. Number of subjects needing at least one dose modification

    Time frame: 25 months

07

Study locations

1 site
  • Odessa National Medical University, Odessa Regional Children's Hospital
    Odessa, Ukraine
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2016 to primary completion in Oct 2017, 21 months.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2017
First posted
Oct 16, 2017
StartActual
Jan 18, 2016
Primary completionActual
Oct 27, 2017
CompletionActual
May 15, 2019
Last update
Apr 20, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 20, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT03309891
Lead sponsor
Genexine, Inc.
Responsible party
Sponsor
First posted
Oct 16, 2017
Start date
Jan 18, 2016
Primary completion
Oct 27, 2017
Completion
May 15, 2019
Last update
Apr 20, 2020

Study contacts

Jungwon Woo
study director · Genexine, Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion